Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
AOD-9604 vs Lixisenatide (Adlyxin)
An educational, source-based comparison of AOD-9604 and Lixisenatide (Adlyxin) — how each peptide works, what it's researched for, and what to know before going deeper.
A modified 16-amino-acid fragment (177–191) of human growth hormone, engineered to retain the lipolytic activity of GH without its growth or insulin-resistance effects. Research suggests it stimulates lipolysis and inhibits lipogenesis.
- Obesity (clinical trials did not meet endpoints)
- Osteoarthritis / cartilage repair (current research direction)
- Localized adipose research
- • Not FDA-approved as a therapeutic.
- • Has GRAS status in some food contexts (Australia), not equivalent to drug approval.
Short-acting GLP-1 agonist focused on postprandial glucose.
Exendin-4 derivative with potent postprandial glucose-lowering effect via delayed gastric emptying and enhanced insulin response.
- Type 2 diabetes
- Postprandial hyperglycemia
- • FDA-approved.
- • GI side effects common.
AOD-9604 vs Lixisenatide (Adlyxin) — Key differences
- Class: AOD-9604 is classified as Metabolic · Lipolysis, while Lixisenatide (Adlyxin) is GLP-1 Agonist · Metabolic.
- Primary research focus: AOD-9604 — obesity (clinical trials did not meet endpoints); Lixisenatide (Adlyxin) — type 2 diabetes.
- Tag: Fat loss vs FDA-Approved · Metabolic.